News | April 01, 2023
ProBioGen delivers strong 2022 performance
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
Natural Capsules Limited's shareholding will be reduced to 89.99%
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
The new project further expands the partner's long-term collaboration on new technologies for R&D
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Subscribe To Our Newsletter & Stay Updated
